Studies on left ventricular hypertrophy regression in arterial hypertension:: A clear message for the clinician?

被引:17
作者
Cuspidi, Cesare [1 ,2 ]
Esposito, Arturo [2 ,3 ]
Negri, Francesca [2 ]
Sala, Carla [3 ,4 ,5 ]
Masaidi, Meilike [3 ]
Giudici, Valentina [2 ]
Zanchetti, Alberto [4 ,5 ]
Mancia, Giuseppe [1 ,4 ,5 ]
机构
[1] Univ Milano Bicocca, Dept Clin Med & Prevent, Milan, Italy
[2] Policlin Monza, Monza, Italy
[3] Osped Maggiore, Policlin Mangiagalli & Regina Elena, IRCCS, Inst Med Cardiovascolare, Modena, Italy
[4] Univ Milan, Ctr Interuniv Fisiol Clin & Ipertens, I-20122 Milan, Italy
[5] Ist Auxol Italiano, Milan, Italy
关键词
D O I
10.1038/ajh.2007.85
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
BACKGROUND Evidence-based medicine should provide clear and unbiased information to clinicians. We conducted an analysis on published randomized trials evaluating the effects of anti hypertensive therapy on left ventricular (LV) morphology assessed by echocardiography to investigate (i) the consistency of criteria used for definition of LV hypertrophy (LVH) and (ii) the consistency of the way LVH regression and blood pressure (13P) control were reported. METHODS Studies identified by a PubMed search were eligible for inclusion in the analysis, if they fulfilled the following criteria: (i) publication in a peer-reviewed journal within the last 12 years; (ii) double blind, randomized, controlled, parallel-group design; (iii) numerosity of at least 50 adult hypertensive subjects; (iv) follow-up duration of at least 6 months; (v) comparison between single-drugs or association regimens; (vi) LV mass (LVM) or wall thickness measured by echocardiography. RESULTS Thirty-nine trials, including 9,162 hypertensive subjects of both genders in 78 active treatment arms or in 6 placebo arms were identified. Definition of LVH was provided by 34 studies (87.1 %) according to 19 different criteria. All trials evaluated LVH regression as the absolute or relative changes of continuous variables such as LVM index (LVMI) or LV wall thickness. Data concerning prevalence rates of LVM normalization were reported in 12 studies (30.7%). The percentage of patients reaching BP target (< 140/90 mm Hg) was reported in 11 studies (28.2%). CONCLUSIONS Our findings indicate that (i) definition of hypertensive LVH phenotype is extremely variable, and (ii) no precise information on LVH regression rates or changes in LV geometrical patterns, as well as on target BP, is provided by the majority of papers.
引用
收藏
页码:458 / 463
页数:6
相关论文
共 53 条
[1]   Cardiac structural and functional changes during long-term anti hypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA) [J].
Agabiti-Rosei, E ;
Trimarco, B ;
Muiesan, ML ;
Reid, J ;
Salvetti, A ;
Tang, R ;
Hennig, M ;
Baurecht, H ;
Parati, G ;
Mancia, G ;
Zanchetti, A .
JOURNAL OF HYPERTENSION, 2005, 23 (05) :1091-1098
[2]   ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study [J].
AgabitiRosei, E ;
Ambrosioni, E ;
DalPalu, C ;
Muiesan, ML ;
Zanchetti, A .
JOURNAL OF HYPERTENSION, 1995, 13 (11) :1325-1334
[3]  
Avanza A C Jr, 2000, Arq Bras Cardiol, V74, P103
[4]  
Beltman Frank W., 1998, Blood Pressure, V7, P109
[5]   LEFT-VENTRICULAR MASS AND RISK OF STROKE IN AN ELDERLY COHORT - THE FRAMINGHAM HEART-STUDY [J].
BIKKINA, M ;
LEVY, D ;
EVANS, JC ;
LARSON, MG ;
BENJAMIN, EJ ;
WOLF, PA ;
CASTELLI, WP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (01) :33-36
[6]   One-year study of felodipine or placebo for stage 1 isolated systolic hypertension [J].
Black, HR ;
Elliott, WJ ;
Weber, MA ;
Frishman, WH ;
Strom, JA ;
Liebson, PR ;
Hwang, CT ;
Ruff, DA ;
Montoro, R ;
DeQuattro, V ;
Zhang, DY ;
Schleman, MM ;
Klibaner, MI .
HYPERTENSION, 2001, 38 (05) :1118-1123
[7]   Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study [J].
Cuspidi, C ;
Muiesan, ML ;
Valagussa, L ;
Salvetti, M ;
Di Biagio, C ;
Agabiti-Rosei, E ;
Magnani, B ;
Zanchetti, A .
JOURNAL OF HYPERTENSION, 2002, 20 (11) :2293-2300
[8]   Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey [J].
Cuspidi, C ;
Ambrosioni, E ;
Mancia, G ;
Pessina, AC ;
Trimarco, B ;
Zanchetti, A .
JOURNAL OF HYPERTENSION, 2002, 20 (07) :1307-1314
[9]   Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy [J].
Dahlof, B ;
Zanchetti, A ;
Diez, J ;
Nicholls, MG ;
Yu, CM ;
Barrios, V ;
Aurup, P ;
Smith, RD ;
Johansson, M .
JOURNAL OF HYPERTENSION, 2002, 20 (09) :1855-1864
[10]   Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass:: the PICXEL study [J].
Dahlof, Bjoern ;
Gosse, Philippe ;
Gueret, Pascal ;
Dubourg, Olivier ;
de Simone, Giovanni ;
Schmieder, Roland ;
Karpov, Yuri ;
Garcia-Puig, Juan ;
Matos, Lajos ;
De Leeuw, Peter W. ;
Degaute, Jean-Paul ;
Magometschnigg, Dieter .
JOURNAL OF HYPERTENSION, 2005, 23 (11) :2063-2070